1. 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Emens, Leisha; Beeram, Muralidhar; Hamilton, Erika; Piha-Paul, Sarina; Odegard, Valerie; Hamke, Sue; Hunder, Naomi; Klempner, Samuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Emens, Leisha; Beeram, Muralidhar; Hamilton, Erika; Piha-Paul, Sarina; Odegard, Valerie; Hamke, Sue; Hunder, Naomi; Klempner, Samuel Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A343 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager. (10th December 2020) Authors: Piha-Paul, Sarina; Starodub, Alexander; Karim, Raghad; Shafique, Michael; Suarez, Gabriel Tinoco; Ruegg, Curtis; Smith, Victoria; Chun, Patrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager. (9th November 2020) Authors: Piha-Paul, Sarina; Starodub, Alexander; Karim, Raghad; Shafique, Michael; Suarez, Gabriel Tinoco; Ruegg, Curtis; Smith, Victoria; Chun, Patrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (10th December 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2. (9th November 2020) Authors: Powderly, John; Carthon, Bradley; Ernstoff, Marc; Olszanski, Anthony; Wrangle, John; Shields, Anthony; Piha-Paul, Sarina; Curtis, Kelly; Bidollari, Ilda; Du, Yangchun; Sun, Lei; Putiri, Emily; Wang, Yan; Losey, Heather; Dezube, Bruce; Dezube, Bruce; Vaishampayan, Ulka Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A398 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. (10th December 2020) Authors: Davar, Diwakar; Simonelli, Matteo; Gutierrez, Martin; Calvo, Emiliano; Melear, Jason; Piha-Paul, Sarina; Richards, Donald; Dallos, Matthew; Parameswaran, Janaki; Kumar, Vinit; Zhao, Xiaochen; Dutta, Santanu; Melero, Ignacio Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. (9th November 2020) Authors: Davar, Diwakar; Simonelli, Matteo; Gutierrez, Martin; Calvo, Emiliano; Melear, Jason; Piha-Paul, Sarina; Richards, Donald; Dallos, Matthew; Parameswaran, Janaki; Kumar, Vinit; Zhao, Xiaochen; Dutta, Santanu; Melero, Ignacio Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗